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Abstract 
Purpose: To synthesize some acetamide derivatives bearing azinane and 1,3,4-oxadiazole heterocyclic 
cores and to evaluate their antibacterial potentials. 
Methods: Ethyl piperidin-4-carboxylate (2) was converted to ethyl 1-[(4-chlorophenyl)sulfonyl]piperidin-
4-carboxylate (3), 1-[(4-chlorophenyl)sulfonyl]piperidin-4-carbohydrazide (4) and 5-[1-(4-
chlorophenylsulfonyl)-4-piperidinyl]-1,3,4-oxadiazol-2-thiol (5) using three consecutive steps. The target 
molecules, 5-{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-2-{[N-(substituted)-2-acetamoyl]thio]}-1,3,4-
oxadiazole (8a-n) were synthesized by stirring 5 and N-aryl-2-bromoacetamides (7a-n) in an aprotic 
polar solvent. The structures were corroborated by infrared (IR), electron impact mass spectrometry (EI-
MS) and proton/carbon nuclear magnetic resonance (1H/13C-NMR) spectroscopic techniques. The 
evaluation of antibacterial activity was based on the effect on the increase in absorbance of the broth 
medium due to log phase microbial growth.  
Results: Compound 8g bearing a 2-methylphenyl group was the most the active growth inhibitor of 
Salmonella typhi, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus 
subtilis bacterial strains with minimum inhibitory concentrations (MIC) of 10.63±0.97, 10.31±1.00, 10.45 
± 0.94 and 11.77±5.00 µM, respectively. Ciprofloxacin was used as reference standard. 
Conclusion: All the synthesized compounds are moderate inhibitors but relatively more active against 
Gram-negative bacterial strains. 5-{1-[(4-Chlorophenyl)sulfonyl]piperidin-4-yl}-2-{[N-(2-methylphenyl)-2-
acetamoyl]thio]}-1,3,4-oxadiazole (8g) is the most active growth inhibitor of all the strains except 
Staphylococcus aureus. 
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The search for new drug candidates with more 
bioactivity potential is a key research interest in 
synthetic organic chemistry [1]. The derivatives 
of heterocyclic compounds have been found to 
be bioactive, including naturally occurring and 
synthetically prepared ones [2]. Among these 
compounds, 1,3,4-oxadiazole derivatives have 
been synthesized and evaluated for a number of 
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biological activities including antidepressant, 
anticonvulsant, anticancer, antimicrobial, etc., 
during the last two decades [2-11]. Another 
bioactive heterocyclic moiety, piperidine or 
azinane, is found to be a part of many natural 
and synthetic bioactive compounds [12]. 
Furthermore, this moiety has applications as food 
additives, solvents, curing agents for rubber and 
intermediates for inorganic synthesis [13,14]. 
These different bioactive heterocyclic moieties 
have been included as a single unit in target 
molecules with the aim of possibly enhancing 






Chemical reagents were purchased from Sigma 
Aldrich and Alfa Aesar through local suppliers. 
The solvents of analytical grade were also 
obtained from local suppliers. The purity of final 
compounds was verified by thin-layer 
chromatography (TLC) performed on silica gel-
coated aluminum plates. n-Hexane and ethyl 
acetate were employed as the mobile phase. The 
TLC plates were visualized under a UV254 lamp. 
A Griffin and George apparatus was used to 
determine melting points, which were 
uncorrected. A Jasco-320-A spectrophotometer, 
Bruker spectrometer and JMS-HX-110 
spectrometer were used to record IR (potassium 
bromide pellet method), 1H-NMR (in CHCl3-d1, at 
300 & 400 MHz) & 13C-NMR (in CHCl3-d1, at 100 
MHz) and EIMS spectra, respectively. 
 
Synthesis of ethyl 1-[(4-chlorophenyl) 
sulfonyl]piperidin-4-carboxylate (3) 
 
4-Chlorobenzenesulfonyl chloride (1; 0.05 mol) 
was stirred with ethyl piperidin-4-carboxylate (2; 
0.05 mol) in water for 3 hours. The pH was 
adjusted to 9 - 10 with 15 % Na2CO3 during the 
reaction. The reaction was monitored by TLC. 
Chilled distilled water was added to the reaction 
mixture to obtain the precipitate of compound 3. 
The formed precipitate was collected by filtration, 
washed and dried. 
 
Synthesis of 1-[(4-chlorophenyl)sulfonyl] 
piperidin-4-carbohydrazide (4) 
 
Compound 3 (0.04 mol) was refluxed with 
hydrazine hydrate (0.04 mol) in ethanol for 2.5 
hours. The reaction was monitored by TLC. After 
addition of distilled water, the precipitate was 






Potassium hydroxide (0.04 mol) and carbon 
disulfide (0.08 mol) were refluxed for 5 hours with 
compound 4 (0.04 mol) in ethanol. The reaction 
was monitored by TLC. Cold distilled water and 
dilute HCl (to adjust pH to 2 - 3) were added to 
precipitate the target compound. The product 
was obtained by filtration, washed, dried and re-
crystallized from methanol.  
 
Synthesis of N-aryl-2-bromoacetamides (7a-n) 
 
Aryl amines (6a-n; 0.02 mol) were stirred with 2-
bromoacetyl bromide (0.02 mol) in distilled water 
for 1 hour. The pH was maintained at 9 - 10 with 
15 % Na2CO3 during the reaction. Completion of 
reaction was confirmed by TLC. The product was 
obtained after filtration, washing and drying. 
 




Compound 5 (0.005 mol) was stirred with LiH 
(0.005 mol) in DMF for half an hour. Equimolar 
N-aryl-2-bromoacetamides (7a-n) were added 
and the mixture was stirred for 3 - 4 hours. 
Completion of reaction was monitored by TLC. 
Cold distilled water was added to form the 
precipitate, which was filtered out, washed and 
dried. 
 
Antibacterial activity assay  
 
The antibacterial activity assay was performed 
according to the protocol reported in the literature 
[15-17], in sterile 96-well microplates under 
aseptic conditions. The increase in absorbance 
of broth medium was noted which is directly 
related to log phase of microbial growth. 
 
Statistical analysis  
 
Statistical analysis using Microsoft Excel 2010 
was based on three independent experiments, 
and the results are expressed as mean ± SEM. 
The minimum inhibitory concentration (MIC) was 
determined with suitable dilutions (5 - 30 µg/well) 
for each compound and the results were 
analyzed using EZ-Fit software (Perrella 
Scientific Inc, Amherst, USA). The statistical 
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The protocol for synthesis of some new N-
substituted acetamide derivatives of azinane 






































































Figure 1: Protocol for synthesis of N-substituted acetamide derivatives of azinane bearing 1,3,4-
oxadiazole. Reagents & conditions: (I) 15 % Na2CO3 solution, H2O, stir for 3 hours. (II) N2H4.H2O, 
EtOH, reflux for 2.5 hours. (III) CS2, KOH (s), EtOH, reflux for 5 hours. (IV) BrCH2COBr, 15 % Na2CO3 
solution, H2O, stir for 1 hour. (V) Dimethyl formamide, LiH, stir for 3 - 4 hours. 
 
Table 1: Different substituted aryl group 
 
Comp R Comp R Comp R 
8a 2-CH3, 4-CH3 8f 3-CH3, 5-CH3 8k 4-OCH2CH3 
8b 2-CH3, 3-CH3 8g 2-CH3 8l 2-OCH2CH3 
8c 2-CH3, 5-CH3 8h 4-CH3 8m 2-CH2CH3, 6-CH3 
8d 2-CH3, 6-CH3 8i 2-CH2CH3 8n 2-OCH3 
8e 3-CH3, 4-CH3 8j 4-CH2CH3   
 
Figure 1 and different N-substituted groups are 
given in Table 1. The spectral characterization of 
synthesized compounds is described below. 
 







White amorphous solid; Yield: 84 %; M.P. 139-
140 °C; M.F.: C23H25ClN4O4S2; M.M.: 521 gmol-1; 
IR (KBr, υmax, cm-1): 3312, 3043, 1648, 1666, 
1603, 1385, 1173, 1034, 678; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.60 (br.s, 1H, -NH), 7.70 (d, 
J = 8.4 Hz, 1H, H-6""), 7.68 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.50 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
6.98 (d, J = 8.8 Hz, 1H, H-5""), 6.96 (s, 1H, H-
3""), 3.96 (s, 2H, H-2"'), 3.69-3.66 (m, 2H, He-2' & 
He-6'), 2.95-2.89 (m, 1H, H-4'), 2.62 (dt, J = 12.8, 
2.8 Hz, 2H, Ha-2' & Ha-6'), 2.26 (s, 3H, CH3-4""), 
2.15 (s, 3H, CH3-2""), 2.14-2.12 (m, 2H, He-3' & 
He-5'), 1.99-1.96 (m, 2H, Ha-3' & Ha-5'); 13C-NMR 
(CDCl3, 100 MHz): δ (ppm) 169.4 (C-5), 165.3 
(C-2), 165.1 (C-1"'), 139.5 (C-1"), 135.1 (C-4"), 
134.8 (C-1""), 132.9 (C-2""), 132.4 (C-4""), 131.2 
(C-5""), 129.5 (C-3" & C-5"), 129.0 (C-2" & C-6"), 
127.2 (C-3""), 122.6 (C-6""), 44.9 (C-2' & C-6'), 
35.9 (C-2"'), 32.4 (C-4'), 28.1 (C-3' & C-5'), 20.8 
(CH3-4""), 17.8 (CH3-2""); EIMS (m/z): 523 
[M+2]+, 521 [M]+, 300 [C12H13ClN2O3S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 
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White crystalline solid; Yield: 79 %; M.P. 172-173 
°C; M.F.: C23H25ClN4O4S2; M.M.: 521 gmol-1; IR 
(KBr, υmax, cm-1): 3308, 3042, 1646, 1661, 1608, 
1387, 1175, 1032, 632; 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 8.65 (br.s, 1H, -NH), 7.69 (d, J = 
8.4 Hz, 2H, H-2" & H-6"), 7.54 (d, J = 8.0 Hz, 1H, 
H-6""), 7.50 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 7.06 
(t, J = 8.0 Hz, 1H, H-5""), 6.98 (d, J = 7.6 Hz, 1H, 
H-4""), 3.97 (s, 2H, H-2"'), 3.73-3.70 (m, 2H, He-
2' & He-6'), 2.90-2.85 (m, 1H, H-4'), 2.58 (dt, J = 
10.4, 2.0 Hz, 2H, Ha-2' & Ha-6'), 2.26 (s, 3H, CH3-
3""), 2.15-2.10 (m, 2H, He-3' & He-5'), 2.09 (s, 3H, 
CH3-2""), 2.02-1.95 (m, 2H, Ha-3' & Ha-5'); EIMS 
(m/z): 523 [M+2]+, 521 [M]+, 300 
[C12H13ClN2O3S]•+, 286 [C12H13ClNO3S]+, 258 
[C11H13ClNO2S]+, 175 [C6H4ClO2S]+, 148 






Off-white amorphous solid; Yield: 76 %; M.P. 
166-167 °C; M.F.: C23H25ClN4O4S2; M.M.: 521 
gmol-1; IR (KBr, υmax, cm-1): 3316, 3048, 1642, 
1660, 1606, 1386, 1178, 1030, 676; 1H-NMR 
(CDCl3, 400 MHz): δ (ppm) 8.53 (br.s, 1H, -NH), 
7.15 (s, 1H, H-6""), 7.63 (d, J = 8.4 Hz, 2H, H-2" 
& H-6"), 7.46 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
7.06 (d, J = 8.4 Hz, 1H, H-3""), 6.91 (d, J = 8.0 
Hz, 1H, H-4""), 3.94 (s, 2H, H-2"'), 3.68-3.64 (m, 
2H, He-2' & He-6'), 2.97-2.93 (m, 1H, H-4'), 2.59 
(dt, J = 12.8, 2.8 Hz, 2H, Ha-2' & Ha-6'), 2.31 (s, 
3H, CH3-2""), 2.20 (s, 3H, CH3-5""), 2.16-2.13 (m, 
2H, He-3' & He-5'), 1.98-1.94 (m, 2H, Ha-3' & Ha-
5'); EIMS (m/z): 523 [M+2]+, 521 [M]+, 300 
[C12H13ClN2O3S]•+, 286 [C12H13ClNO3S]+, 258 
[C11H13ClNO2S]+, 175 [C6H4ClO2S]+, 148 






Off-white amorphous solid; Yield: 86 %; M.P. 96-
97 °C; M.F.: C23H25ClN4O4S2; M.M.: 521 gmol-1; 
IR (KBr, υmax, cm-1): 3346, 3038, 1644, 1680, 
1616, 1376, 1158, 1020, 656; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.46 (br.s, 1H, -NH), 7.65 (d, 
J = 8.0 Hz, 2H, H-2" & H-6"), 7.49 (d, J = 8.0 Hz, 
2H, H-3" & H-5"), 7.10-7.07 (m, 3H, H-3"" to H-
5""), 3.95 (s, 2H, H-2"'), 3.68-3.65 (m, 2H, He-2' & 
He-6'), 2.98-2.93 (m, 1H, H-4'), 2.55 (dt, J = 12.8, 
2.8 Hz, 2H, Ha-2' & Ha-6'), 2.23 (s, 6H, CH3-2"" & 
CH3-6""), 2.18-2.15 (m, 2H, He-3' & He-5'), 2.02-
1.96 (m, 2H, Ha-3' & Ha-5'); EIMS (m/z): 523 
[M+2]+, 521 [M]+, 300 [C12H13ClN2O3S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 






White amorphous solid; Yield: 71 %; M.P. 196-
197 °C; M.F.: C23H25ClN4O4S2; M.M.: 521 gmol-1; 
IR (KBr, υmax, cm-1): 3342, 3034, 1642, 1684, 
1612, 1372, 1154, 1022, 655; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.83 (br.s, 1H, -NH), 7.69 (d, 
J = 8.4 Hz, 2H, H-2" & H-6"), 7.50 (d, J = 8.4 Hz, 
2H, H-3" & H-5"), 7.26 (s, 1H, H-2""), 7.22 (d, J = 
8.4 Hz, 1H, H-5""), 7.03 (d, J = 8.0 Hz, 1H, H-
6""), 3.90 (s, 2H, H-2"'), 3.73-3.70 (m, 2H, He-2' & 
He-6'), 2.88-2.84 (m, 1H, H-4'), 2.59 (dt, J = 10.4, 
2.0 Hz, 2H, Ha-2' & Ha-6'), 2.21 (s, 3H, CH3-4""), 
2.18 (s, 3H, CH3-3""), 2.16-2.12 (m, 2H, He-3' & 
He-5'), 2.02-1.96 (m, 2H, Ha-3' & Ha-5'); EIMS 
(m/z): 523 [M+2]+, 521 [M]+, 300 
[C12H13ClN2O3S]•+, 286 [C12H13ClNO3S]+, 258 
[C11H13ClNO2S]+, 175 [C6H4ClO2S]+, 148 






White amorphous solid; Yield: 74 %; M.P. 207-
208 °C; M.F.: C23H25ClN4O4S2; M.M.: 521 gmol-1; 
IR (KBr, υmax, cm-1): 3345, 3037, 1645, 1687, 
1615, 1376, 1157, 1022, 657; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.54 (br.s, 1H, -NH), 7.64 (d, 
J = 8.4 Hz, 2H, H-2" & H-6"), 7.52 (d, J = 8.4 Hz, 
2H, H-3" & H-5"), 7.14 (s, 2H, H-2"" & H-6""), 
6.97 (s, 1H, H-4''''), 3.95 (s, 2H, H-2"'), 3.69-3.65 
(m, 2H, He-2' & He-6'), 2.99-2.95 (m, 1H, H-4'), 
2.57 (dt, J = 12.8, 2.8 Hz, 2H, Ha-2' & Ha-6'), 2.28 
(s, 6H, CH3-3"" & CH3-5""), 2.19-2.16 (m, 2H, He-
3' & He-5'), 2.01-1.97 (m, 2H, Ha-3' & Ha-5'); 
EIMS (m/z): 523 [M+2]+, 521 [M]+, 300 
[C12H13ClN2O3S]•+, 286 [C12H13ClNO3S]+, 258 
[C11H13ClNO2S]+, 175 [C6H4ClO2S]+, 148 






White amorphous; Yield: 79 %; M.P. 148-149 °C; 
M.F.: C22H23ClN4O4S2; M.M.: 507 gmol-1; IR (KBr, 
υmax, cm-1): 3340, 3031, 1631, 1683, 1611, 1372, 
1159, 1027, 651; 1H-NMR (CDCl3, 400 MHz): δ 
(ppm) 8.73 (br.s, 1H, -NH), 7.88 (d, J = 8.0 Hz, 
1H, H-6""), 7.69 (d, J = 8.8 Hz, 2H, H-2" & H-6"), 
7.50 (d, J = 8.8 Hz, 2H, H-3" & H-5"), 7.17 (t, J = 
7.6 Hz, 1H, H-5""), 7.14 (d, J = 8.0 Hz, 1H, H-
3""), 7.04 (t, J = 7.6 Hz, 1H, H-4""), 3.97 (s, 2H, 
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H-2"'), 3.70-3.67 (m, 2H, He-2' & He-6'), 2.91-2.85 
(m, 1H, H-4'), 2.61 (dt, J = 12.0, 2.4 Hz, 2H, Ha-2' 
& Ha-6'), 2.20 (s, 3H, CH3-2""), 2.15-2.11 (m, 2H, 
He-3' & He-5'), 2.02-1.93 (m, 2H, Ha-3' & Ha-5'); 
EIMS (m/z): 509 [M+2]+, 507 [M]+, 300 
[C12H13ClN2O3S]•+, 286 [C12H13ClNO3S]+, 258 
[C11H13ClNO2S]+, 175 [C6H4ClO2S]+, 134 






White amorphous solid; Yield: 77 %; M.P. 195-
196 °C; M.F.: C22H23ClN4O4S2; M.M.: 507 gmol-1; 
IR (KBr, υmax, cm-1): 3344, 3034, 1640, 1683, 
1617, 1371, 1156, 1029, 658; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.52 (br.s, 1H, -NH), 7.67 (d, 
J = 8.0 Hz, 2H, H-2" & H-6"), 7.59 (d, J = 8.4 Hz, 
2H, H-3" & H-5"), 7.34 (d, J = 8.0 Hz, 2H, H-2'''' & 
H-6''''), 6.97 (d, J = 8.0 Hz, 2H, H-3'''' & H-5''''), 
3.93 (s, 2H, H-2"'), 3.70-3.65 (m, 2H, He-2' & He-
6'), 3.01-2.96 (m, 1H, H-4'), 2.58 (dt, J = 12.8, 
2.8 Hz, 2H, Ha-2' & Ha-6'), 2.28 (s, 3H, CH3-4""), 
2.17-2.13 (m, 2H, He-3' & He-5'), 2.01-1.95 (m, 
2H, Ha-3' & Ha-5'); EIMS (m/z): 509 [M+2]+, 507 
[M]+, 300 [C12H13ClN2O3S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 






White amorphous solid; Yield: 84 %; M.P. 134-
135 °C; M.F.: C23H25ClN4O4S2; M.M.: 521 gmol-1; 
IR (KBr, υmax, cm-1): 3320, 3021, 1650, 1671, 
1602, 1393, 1170, 1034, 672; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.71 (br.s, 1H, -NH), 7.82 (d, 
J = 8.0 Hz, 1H, H-6""), 7.69 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.50 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
7.20 (t, J = 7.2 Hz, 1H, H-5""), 7.18 (d, J = 7.2 
Hz, 1H, H-3""), 7.09 (t, J = 7.2 Hz, 1H, H-4""), 
3.98 (s, 2H, H-2"'), 3.69-3.66 (m, 2H, He-2' & He-
6'), 2.90-2.87 (m, 1H, H-4'), 2.62 (dt, J = 11.6, 
2.8 Hz, 2H, Ha-2' & Ha-6'), 2.52 (q, J = 7.6 Hz, 
2H, CH3CH2-2""), 2.15-2.11 (m, 2H, He-3' & He-
5'), 2.02-1.95 (m, 2H, Ha-3' & Ha-5'), 1.08 (t, J = 
7.6 Hz, 3H, CH3CH2-2""); EIMS (m/z): 523 
[M+2]+, 521 [M]+, 300 [C12H13ClN2O3S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 






Off-white amorphous solid; Yield: 79 %; M.P. 
200-201 °C; M.F.: C23H25ClN4O4S2; M.M.: 521 
gmol-1; IR (KBr, υmax, cm-1): 3332, 3023, 1637, 
1654, 1587, 1454, 1230, 1024, 718; 1H-NMR 
(CDCl3, 400 MHz): δ (ppm) 8.94 (br.s, 1H, -NH), 
7.69 (d, J = 8.8 Hz, 2H, H-2" & H-6"), 7.50 (d, J = 
8.4 Hz, 2H, H-3" & H-5"), 7.40 (d, J = 8.0 Hz, 2H, 
H-2"" & H-6""), 7.11 (d, J = 8.4 Hz, 2H, H-3"" & 
H-5""), 3.91 (s, 2H, H-2"'), 3.73-3.70 (m, 2H, He-
2' & He-6'), 2.89-2.83 (m, 1H, H-4'), 2.61 (q, J = 
8.0 Hz, 2H, CH3CH2-4""), 2.60-2.55 (m, 2H, Ha-2' 
& Ha-6'), 2.16-2.12 (m, 2H, He-3' & He-5'), 2.02-
1.92 (m, 2H, Ha-3' & Ha-5'), 1.18 (t, J = 7.6 Hz, 
3H, CH3CH2-4""); EIMS (m/z): 523 [M+2]+, 521 
[M]+, 300 [C12H13ClN2O3S]•+, 286 [C12H13Cl 
NO3S]+, 258 [C11H13ClNO2S]+, 175 [C6H4ClO2S]+, 






Pink amorphous solid; Yield: 75 %; M.P. 189-190 
°C; M.F.: C23H25ClN4O5S2; M.M.: 537 gmol-1; IR 
(KBr, υmax, cm-1): 3335, 3024, 1643, 1651, 1583, 
1452, 1232, 1021, 713; 1H-NMR (CDCl3, 400 
MHz): δ (ppm) 8.86 (br.s, 1H, -NH), 7.65 (d, J = 
8.4 Hz, 2H, H-2" & H-6"), 7.52 (d, J = 8.4 Hz, 2H, 
H-3" & H-5"), 6.94 (d, J = 8.4 Hz, 2H, H-2'''' & H-
6''''), 6.76 (d, J = 8.4 Hz, 2H, H-3'''' & H-5''''), 3.93 
(s, 2H, H-2"'), 3.84 (q, J = 7.6, 2H, CH3CH2O-
4""), 3.72-3.68 (m, 2H, He-2' & He-6'), 2.91-2.87 
(m, 1H, H-4'), 2.63-2.58 (m, 2H, Ha-2' & Ha-6'), 
2.15-2.10 (m, 2H, He-3' & He-5'), 2.01-1.94 (m, 
2H, Ha-3' & Ha-5'), 1.32 (t, J = 7.6 Hz, 3H, 
CH3CH2O-4""); EIMS (m/z): 539 [M+2]+, 537 [M]+, 
300 [C12H13ClN2O3S]•+, 286 [C12H13ClNO3S]+, 
258 [C11H13ClNO2S]+, 175 [C6H4ClO2S]+, 164 






White amorphous solid; Yield: 78 %; M.P. 198-
199 °C; M.F.: C23H25ClN4O5S2; M.M.: 537 gmol-1; 
IR (KBr, υmax, cm-1): 3337, 3026, 1644, 1656, 
1587, 1454, 1236, 1024, 716; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.99 (br.s, 1H, -NH), 8.29 (d, 
J = 8.0 Hz, 1H, H-6""), 7.68 (d, J = 8.8 Hz, 2H, H-
2" & H-6"), 7.49 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
7.01 (dt, J = 8.0, 1.2 Hz, 1H, H-5""), 6.90 (t, J = 
8.0 Hz, 1H, H-4""), 6.88 (d, J = 8.0 Hz, 1H, H-
3""), 4.05 (q, J = 6.8 Hz, 2H, CH3CH2O-2""), 4.02 
(s, 2H, H-2"'), 3.69-3.66 (m, 2H, He-2' & He-6'), 
2.87-2.83 (m, 1H, H-4'), 2.60 (dt, J = 12.8, 2.8 
Hz, 2H, Ha-2' & Ha-6'), 2.14-2.09 (m, 2H, He-3' & 
He-5'), 2.02-1.93 (m, 2H, Ha-3' & Ha-5'), 1.42 (t, J 
= 7.2 Hz, 3H, CH3CH2O-2""); EIMS (m/z): 539 
[M+2]+, 537 [M]+, 300 [C12H13ClN2O3S]•+, 286 
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[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 






Light brown amorphous solid; Yield: 73 %; M.P. 
98-99 °C; M.F.: C24H27ClN4O4S2; M.M.: 535 gmol-
1; IR (KBr, υmax, cm-1): 3338, 3027, 1637, 1658, 
1588, 1456, 1238, 1028, 715; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.78 (br.s, 1H, -NH), 7.68 (d, 
J = 8.4 Hz, 2H, H-2" & H-6"), 7.54 (d, J = 8.4 Hz, 
2H, H-3" & H-5"), 6.98-7.14 (m, 3H, H-3"" to H-
5""), 3.94 (s, 2H, H-2"'), 3.75-3.69 (m, 2H, He-2' & 
He-6'), 2.96-2.90 (m, 1H, H-4'), 2.46 (q, J = 7.6 
Hz, 2H, CH3CH2-2""), 2.62-2.58 (m, 2H, Ha-2' & 
Ha-6'), 2.15-2.12 (m, 2H, He-3' & He-5'), 2.01-1.95 
(m, 2H, Ha-3' & Ha-5'), 1.94 (s, 3H, CH3-6''''), 1.02 
(t, J = 7.6 Hz, 3H, CH3CH2-2""); EIMS (m/z): 537 
[M+2]+, 535 [M]+, 300 [C12H13ClN2O3S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 






White amorphous solid; Yield: 86 %; M.P. 142-
143 °C; M.F.: C22H23ClN4O5S2; M.M.: 523 gmol-1; 
IR (KBr, υmax, cm-1): 3330, 3028, 1647, 1650, 
1589, 1450, 1230, 1029, 712; 1H-NMR (CDCl3, 
400 MHz): δ (ppm) 8.94 (br.s, 1H, -NH), 8.28 (d, 
J = 8.0 Hz, 1H, H-6""), 7.69 (d, J = 8.4 Hz, 2H, H-
2" & H-6"), 7.52 (d, J = 8.4 Hz, 2H, H-3" & H-5"), 
7.01 (t, J = 8.4 Hz, 1H, H-5""), 6.92 (t, J = 8.0 Hz, 
1H, H-4""), 6.83 (d, J = 8.0 Hz, 1H, H-3""), 3.98 
(s, 2H, H-2"'), 3.83 (s, 3H, CH3O-2""), 3.70-3.66 
(m, 2H, He-2' & He-6'), 2.89-2.84 (m, 1H, H-4'), 
2.57 (dt, J = 12.8, 2.8 Hz, 2H, Ha-2' & Ha-6'), 
2.16-2.12 (m, 2H, He-3' & He-5'), 2.00-1.95 (m, 
2H, Ha-3' & Ha-5'); EIMS (m/z): 529 [M+2]+, 527 
[M]+, 300 [C12H13ClN2O3S]•+, 286 
[C12H13ClNO3S]+, 258 [C11H13ClNO2S]+, 175 
[C6H4ClO2S]+, 150 [C8H8NO2]+, 122 [C7H8NO]+. 
 
Antibacterial activity  
 
The results of antibacterial activity are given as 
% inhibition and MIC in Table 2 and Table 3, 
respectively. The synthesized compounds 
exhibited better activity against the Gram-
negative bacterial strains used. Compound 8g 
bearing a 2-methylphenyl group was the most 
active against all the Gram-negative bacterial 





Compound 8a was a white amorphous solid with 
a melting point of 139-140 °C, showing a yield of 
84 %. Its molecular mass was justified by the 
molecular ion peak at m/z 521 with an isotopic 
peak at m/z 523. The molecular formula was well 
supported by EIMS spectrum and the proton 
integration curves in 1H-NMR spectrum.  
The IR spectrum absorption peaks (υmax, cm-1) 
confirmed all the functionalities, carbonyl for 
acetamoyl at 1648, sulfamoyl at 1385 and 
oxadiazole at 1666 (C=N), 1173 & 1034 (C-O-C). 
 
 





Gram-negative bacteria Gram-positive bacteria 
S. typhi E. coli P. aeruginosa S. aureus B. subtilis 
8a 52.64±1.09 55.93±2.22 60.77±2.40 47.55±3.00 54.14±0.91 
8b 69.27±1.21 49.07±1.02 62.45±3.27 53.92±1.27 44.19±3.45 
8c 46.36±2.34 53.56±1.71 63.98±4.90 31.37±2.67 44.55±3.43 
8d 54.65±1.56 53.19±2.36 59.59±3.47 53.82±1.99 60.81±0.71 
8e 57.64±0.76 47.18±2.82 45.82±2.45 49.02±2.54 49.55±0.96 
8f 61.45±1.42 48.52±1.57 51.28±0.97 54.31±1.55 49.75±0.76 
8g 62.64±1.00 65.60±0.65 64.69±1.12 47.25±3.04 57.93±1.97 
8h 49.36±2.87 49.81±2.22 30.87±3.72 41.18±3.77 46.11±0.56 
8i 49.55±3.47 52.27±5.00 46.99±1.79 52.94±1.95 48.94±2.47 
8j 55.45±1.88 48.24±1.37 52.14±3.47 44.41±2.87 56.16±1.21 
8k 55.45±2.03 62.36±2.64 54.23±5.00 50.49±1.90 61.62±2.02 
8l 52.82±1.31 53.61±4.54 51.07±2.09 28.04±4.00 53.28±1.67 
8m 55.09±1.82 42.08±3.01 47.24±4.69 43.43±3.24 59.19±3.03 
8n 75.09±2.92 51.02±3.98 48.83±1.38 58.04±2.00 68.43±1.57 
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Ciprofloxacin 91.79±1.45 90.87±0.56 92.13±0.97 90.45±2.98 91.18±1.22 
 
Table 3: MIC of the synthesized compounds 
  
Compound 
MIC( µg/ mL) 
Gram-negative bacteria Gram-positive bacteria 
S. typhi E. coli P. aeruginosa S. aureus B. subtilis 
8a 11.38±1.25 - 12.88±1.06 10.59±1.96 - 
8b 16.65±1.09 13.74±2.53 10.22±1.88 - 15.88±1.50 
8c - 17.56±1.00 13.67±1.38 - - 
8d 13.54±1.71 14.05±0.98 11.35±1.75 14.08±1.15 10.84±1.70 
8e 16.89±1.50 - - - - 
8f 16.46±2.23 - 18.42±0.94 17.19±5.00 - 
8g 10.63±0.97 10.31±1.00 10.45±0.94 - 11.77±5.00 
8h - - - - - 
8i - 18.21±0.34 - 16.83±5.00 - 
8j 17.90±3.45 - 18.79±1.69 - 18.06±5.00 
8k 17.47±1.22 15.78±1.67 17.37±1.25 19.64±2.50 15.12±1.79 
8l 13.90±1.93 11.97±1.98 16.91±1.19 - 17.07±4.93 
8m 15.11±1.17 - - - 14.39±2.79 
8n 15.00±2.15 19.48±2.00 - 16.12±4.86 15.55±4.29 
Ciprofloxacin 7.15±1.29 7.90±1.87 8.21±1.21 8.00±2.98 7.12±2.11 
 
In EIMS spectrum, the mass fragments at m/z 
300 due to partial breakage of 1,3,4-oxadiazole 
ring, at m/z 258 due to 1-[(4-
chlorophenyl)sulfonyl]piperidin-4-yl cation and at 
m/z 148 for N-(2,4-dimethylphenyl)amino 
carbonyl cation collectively corroborated the 
whole structure of the molecule.  
 
The 1H-NMR spectrum displayed two ortho 
coupled doublets with two proton integration at δ 
7.68 (d, J = 8.4 Hz, 2H, H-2" & H-6") and 7.50 (d, 
J = 8.4 Hz, 2H, H-3" & H-5") for the 4-
chlorobenzenesulfonyl group. Two doublets & 
three singlets in aromatic and aliphatic regions, 
at δ 7.70 (d, J = 8.4 Hz, 1H, H-6""), 6.98 (d, J = 
8.8 Hz, 1H, H-5""), 6.96 (s, 1H, H-3""), 2.26 (s, 
3H, CH3-4"") and 2.15 (s, 3H, CH3-2""), 
collectively confirmed the presence of 2,4-
dimethylphenyl ring. Two singlets at δ 8.60 (br.s, 
1H, -NH) and 3.96 (s, 2H, H-2"') were assigned 
to the acetamoyl group. The piperidine or 
azinane moiety showed signals at δ 3.69-3.66 
(m, 2H, He-2' & He-6'), 2.95-2.89 (m, 1H, H-4'), 
2.62 (dt, J = 12.8, 2.8 Hz, 2H, Ha-2' & Ha-6'), 
2.14-2.12 (m, 2H, He-3' & He-5') and 1.99-1.96 
(m, 2H, Ha-3' & Ha-5').  
 
The molecule was also well supported by 13C-
NMR (Broad Band and Distorsionless 
Enhancement by Polarization Transfer). This 
spectrum showed nineteen signals for two 
methyl, five methylene, eight methine and eight 
quaternary carbons. The quaternary carbons 
appeared at δ 169.4 (C-5), 165.3 (C-2), 165.1 (C-
1"'), 139.5 (C-1"), 135.1 (C-4"), 134.8 (C-1""), 
132.9 (C-2"") and 132.4 (C-4""). The methine 
carbons demonstrated six signals at δ 131.2 (C-
5""), 129.5 (C-3" & C-5"), 129.0 (C-2" & C-6"), 
127.2 (C-3""), 122.6 (C-6"") and 32.4 (C-4'). The 
methylene carbons were confirmed by three 
signals at δ 44.9 (C-2' & C-6'), 28.1 (C-3' & C-5') 
and 35.9 (C-2"'). The methyl carbons showed 
two signals at δ 20.8 (CH3-4"") and 17.8 (CH3-
2"").  
 
The analysis of spectral data corroborated the 
structure of 8a to be 5-{1-[(4-
chlorophenyl)sulfonyl]piperidin-4-yl}-2-{[N-(2,4-
dimethylphenyl)-2-acetamoyl]thio]}-1,3,4-
oxadiazole. The structures of the other molecules 
were likewise elucidated from their spectral data. 
 
The synthesized compounds exhibited 
antibacterial activity against Gram-negative 
bacterial strains used. Against S. typhi, 8a 
bearing a 2,4-dimethylphenyl group and 8g 
bearing a 2-methylphenyl group were the most 
active ones with MIC values of 11.38 ± 1.25 and 
10.63 ± 0.97 µg/mL, respectively, compared to 
ciprofloxacin (reference antibiotic) with a MIC of 
7.15 ± 1.29 µg/mL. Against E. coli, the most 
effective were 8g and 8l (2-ethoxyphenyl group) 
with MIC values of 10.31 ± 1.00 and 11.97 ± 1.98 
µg/mL, respectively, compared to the reference 
value of 7.90 ± 1.87 µg/mL. Against P. 
aeruginosa, compounds 8b (2,3-dimethylphenyl 
group), 8d (2,6-dimethylphenyl group) and 8g 
were the most effective with MIC values of 10.22 
± 1.88, 11.35 ± 1.75 and 10.45 ± 0.94 µg/mL, 
respectively, in comparison to the reference of 
8.21 ± 1.21 µg/mL. S. aureus growth was 
effectively inhibited by 8a with a MIC of 10.59 ± 
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1.96 µg/mL relative to 8.00 ± 2.98 µg/mL. B. 
subtilis growth was effectively inhibited by 8d and 
8g with MIC values of 10.84 ± 1.70 and 11.77 ± 
5.00 µg/mL, respectively, with reference to 7.12 
± 2.11 µg/mL. Compound 8g bearing a 2-
methylphenyl group was the most active against 
all the Gram-negative bacterial strains and one of 




All target compounds were synthesized in 
reasonable yields by a series of benign methods. 
The compounds are excellent to moderate 
growth inhibitors of the bacterial strains studied. 
Among these biologically active compounds, 5-
{1-[(4-chlorophenyl)sulfonyl]piperidin-4-yl}-2-{[N-
(2-methylphenyl)-2-acetamoyl]thio]}-1,3,4-
oxadiazole (8g) is the most potent against all the 
strains except S. aureus. This molecule can be 
further evaluated for cytotoxic behavior and may 
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